Wiz Biotech blows the whistle to open up the market
Xiamen Wiz Biotech Co., Ltd is located in Xiamen Biopharmaceutical Port. The company takes rapid diagnosis as its entry point and focuses on gastrointestinal and digestive fields. From research and development, registration and approval, to market access, sales network...... After several years of accumulation, Wiz has established a mature research and development technology platform and sales system.
After the COVID-19 outbreak, Lin Zhikeng led the research and development team quickly invested in the development of antibody test kits.
"In the face of new opportunities emerging from the pandemic crisis, we respond quickly and seize the opportunity to expand the market by applying existing technologies in new areas." Lin said the test kit developed by the company received CE certification from the European Union in March this year and was included in China's export white list of COVID-19 reagents.
Thanks to the study of user usage scenarios, the R&D team of the company innovates in the ease of kit operation and improves the accuracy of kit. At present, the export orders have been sold to millions of people.
Xiamen is the "neighbor" of Positive Biology, and Rexiu (Xiamen) Cell Biotechnology Co., Ltd. continues to increase R&D investment, with a year-on-year growth of 45% in the first half of the year. The company is committed to the research and development of innovative technologies and drugs, focusing on the prevention and treatment of cancer and autoimmune diseases, with a number of core intellectual property rights.
Ding Changfa, associate professor at the School of Economics at Xiamen University, pointed out that the biomedical industry was listed as one of the three strategic emerging industries in Xiamen as early as 2003. After more than ten years of development, Xiamen biomedicine industry has preliminarily realized industrial agglomeration and talent agglomeration, blowing the vanguard of industrial development.
At the Xiamen Bio-pharmaceutical Innovation and Development Conference held in June this year, Xiamen released a series of weighty policies to support the innovation and development of the bio-pharmaceutical industry, proposing to speed up the construction of the city of life science and technology in China.
"The year 2020 is a landmark year for Xiamen's biopharmaceutical industry. The COVID-19 epidemic has brought new development opportunities for the biopharmaceutical industry in Xiamen." Ding Changfei said.
(Source: Xinhuanet.com; Reporter Fu Min)
